久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

USEUROPEAFRICAASIA 中文雙語Fran?ais
World
Home / World / Reporter's Journal

Conquering malaria remains a daunting dilemma, but there's hope

By Chris Davis | China Daily USA | Updated: 2017-04-27 11:18

The war against malaria has made progress over the past decade, but there is still a long way to go, and Chinese researchers are leading the way on more than one front.

Roughly half of the world's population - 3 billion people - still remains at risk.

In 2006, there were 266 million cases a year leading to 750,000 deaths, according to the World Health Organization.

By 2015, the numbers had diminished, but remained huge - 212 million cases, 429,000 deaths.

And a staggering 90 percent of all cases are in Africa.

Dr Deng Changsheng, manager of the department of science and technology at Guangzhou University of Chinese Medicine, told a group of 27 journalists visiting from Africa recently, that strategy used to cause a major decline in malarial regions of China is showing promise in Africa.

The approach is called fast elimination of malaria by source eradication (FEMSE). It involves mass drug administration (MDA) of artemisinin-based combination therapies (ACT) - in other words, clearing an affected population of the malarial parasites by mass drug administration.

Artemisinin, by the way, is the drug that won 85-year-old Chinese pharmacologist Tu Youyou the 2015 Nobel Prize for Medicine. She had mined the recipe, derived from the sweet wormwood plant, from the annals of ancient Chinese medicine. Today it saves hundreds of thousands of lives a year in Africa alone.

The drug has not been cheap, but Deng said the cost could be brought to as low as $15 per person over the next decade. Today it's about $40, according to Deng.

Thanks to a worldwide push, ACT treatments rose from 187 million in 2010 to 311 million in 2015.

The big fear facing the effort right now is that the parasites are showing signs of developing a resistance to artemisinin, the same way some strains of tuberculosis are shunning off some of modern medicine's most potent antibiotics.

"The spread of artemisinin resistance in Africa would be a major setback in the fight against malaria, as ACT is the only effective and widely used anti-malarial treatment at the moment," writes Professor Arnab Pain of King Abdullah University of Science and Technology in the current issue of the New England Journal of Medicine.

"Therefore it is very important to regularly monitor artemisinin resistance on a worldwide scale," he added.

The study, led by Jun Cao of the Institute for Parasitic Diseases in China, found drug-resistant malarial parasites in a Chinese patient who had been in Equatorial Guinea and returned to China. The ACT therapy, which usually takes three days to rid the patient of the disease, took five days in this case.

This "partial resistance", they said, has been noted in other parts of Southeast Asia, and the great fear is that "partial" morphs into "complete".

"This is one of the great challenges facing us in the fight against malaria," the World Health Organization says on its website.

The holy grail of that fight, of course, remains a vaccine, and The Associated Press reports that three African nations have just been chosen to test the world's first malaria vaccine.

WHO announced Monday that Ghana, Kenya and Malawi will begin piloting an injectable vaccine next year with hundreds of thousands of young children, who have been at highest risk of death.

The vaccine, which has partial effectiveness, has the potential to save tens of thousands of lives if used with existing measures, WHO's regional director for Africa, Dr Matshidiso Moeti, said in a statement. The challenge is whether impoverished countries can deliver the required four doses of the vaccine for each child.

The vaccine will be tested on children 5 to 17 months old to see whether its protective effects shown so far in clinical trials can hold up under real-life conditions. At least 120,000 children in each of the three countries will receive the vaccine, which has taken decades of work and hundreds of millions of dollars to develop.

Kenya, Ghana and Malawi were chosen for the vaccine pilot because all have strong prevention and vaccination programs but continue to have high numbers of malaria cases, WHO said. The countries will deliver the vaccine through their existing vaccination programs.

WHO is hoping to wipe out malaria by 2040, despite the increasing resistance problems to both drugs and insecticides used to kill mosquitoes.

The vaccine was developed by GlaxoSmithKline, and the $49 million for the first phase of the pilot is being funded by the global vaccine alliance GAVI, UNITAID and Global Fund to Fight AIDS, Tuberculosis and Malaria.

Contact the writer at chrisdavis@chinadailyusa.com.

 

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
久久久无码人妻精品无码_6080YYY午夜理论片中无码_性无码专区_无码人妻品一区二区三区精99

    91视频91自| 日韩欧美亚洲一区二区| 一区二区三区影院| 欧美日韩亚洲综合在线 欧美亚洲特黄一级 | 久久久亚洲国产美女国产盗摄| 国产精品原创巨作av| 亚洲国产电影在线观看| 日本高清不卡一区| 日本欧美久久久久免费播放网| 久久免费午夜影院| av成人老司机| 无码av中文一区二区三区桃花岛| 日韩一级片在线播放| 丰满亚洲少妇av| 一区二区三区在线不卡| 日韩欧美久久一区| 波多野结衣视频一区| 午夜一区二区三区视频| 久久亚洲一级片| 91浏览器打开| 蜜臀91精品一区二区三区| 国产欧美日韩中文久久| 欧美影院一区二区三区| 久久99精品久久久久| 最新国产精品久久精品| 欧美一级日韩不卡播放免费| 成人av在线网| 亚洲成人综合网站| 久久久精品中文字幕麻豆发布| 色综合天天综合网天天狠天天| 麻豆精品一区二区| 日韩一区在线免费观看| 日韩欧美激情一区| 成人午夜激情片| 午夜欧美视频在线观看| 国产日韩欧美a| 欧美色图免费看| 国产精品996| 午夜国产精品一区| 国产精品婷婷午夜在线观看| 欧美日韩高清一区二区三区| 粉嫩久久99精品久久久久久夜| 亚洲成国产人片在线观看| 国产日产欧产精品推荐色 | 性久久久久久久久| 日本一区二区三区高清不卡| 3d动漫精品啪啪1区2区免费| 成a人片国产精品| 久久精品国产免费| 亚洲精品欧美在线| 国产欧美一区二区三区在线看蜜臀 | 欧美国产日产图区| 4438x成人网最大色成网站| 99精品视频在线免费观看| 蜜桃视频在线观看一区二区| 亚洲欧美色综合| 国产午夜精品久久| 日韩一级二级三级| 欧美影视一区二区三区| 成人av免费网站| 国产自产v一区二区三区c| 午夜精品aaa| 亚洲综合激情网| 中文字幕乱码亚洲精品一区 | 91精品免费在线观看| 一本大道久久a久久精品综合| 国产乱码一区二区三区| 视频一区二区三区在线| 亚洲码国产岛国毛片在线| 日本一区二区视频在线| 久久综合资源网| 在线不卡一区二区| 欧美性受极品xxxx喷水| gogo大胆日本视频一区| 国产精品18久久久久久久久| 麻豆精品久久久| 性做久久久久久免费观看欧美| 亚洲毛片av在线| 综合电影一区二区三区| 亚洲国产精品精华液2区45| 久久综合丝袜日本网| 欧美成人午夜电影| 欧美一区二区在线不卡| 欧美肥妇毛茸茸| 欧美日韩免费观看一区二区三区 | 亚洲欧美日韩久久精品| 国产精品久久久久桃色tv| 久久久国产一区二区三区四区小说 | 欧美日韩综合一区| 色婷婷精品久久二区二区蜜臀av| 成人动漫一区二区三区| 成人伦理片在线| 国产成人av资源| 国产成人免费9x9x人网站视频| 国产毛片精品一区| 国产美女一区二区| 国产成人鲁色资源国产91色综| 国产精品影视在线| 国产精品18久久久| 国产成人免费视频精品含羞草妖精| 国产曰批免费观看久久久| 国产真实乱子伦精品视频| 国产在线国偷精品产拍免费yy| 激情综合一区二区三区| 韩国v欧美v亚洲v日本v| 国产毛片精品国产一区二区三区| 国产综合色在线| 国产不卡视频在线播放| 国产成人日日夜夜| 北条麻妃一区二区三区| 91丨九色丨蝌蚪丨老版| 色激情天天射综合网| 在线观看不卡视频| 欧美日韩视频专区在线播放| 欧美老肥妇做.爰bbww视频| 91精品综合久久久久久| 日韩限制级电影在线观看| 欧美成人vps| 久久无码av三级| 中文字幕av一区二区三区高| 日韩一区在线看| 亚洲影视在线播放| 日韩精品电影在线观看| 激情久久五月天| 成人晚上爱看视频| 一本色道久久综合亚洲aⅴ蜜桃| 欧美日韩视频在线第一区 | 久久99精品视频| 粉嫩av一区二区三区粉嫩| 色先锋aa成人| 91精品国产欧美一区二区18| 久久久午夜精品| ●精品国产综合乱码久久久久| 亚洲一区二区精品久久av| 青青草成人在线观看| 国产精品一卡二| 色综合久久六月婷婷中文字幕| 欧美精品久久久久久久多人混战 | 国产精品影视网| 91丨porny丨国产| 制服丝袜亚洲色图| 久久奇米777| 亚洲黄色小视频| 另类小说欧美激情| 国产99久久久国产精品潘金| 在线精品视频小说1| 日韩一区二区三区在线视频| 中日韩av电影| 亚洲成人动漫在线观看| 狠狠色综合日日| 91无套直看片红桃| 日韩一区二区在线观看视频| 国产精品色呦呦| 午夜在线成人av| 国产激情精品久久久第一区二区 | 8v天堂国产在线一区二区| 国产清纯在线一区二区www| 一区二区三区高清在线| 玖玖九九国产精品| 色婷婷综合五月| www成人在线观看| 亚洲激情校园春色| 久久99热狠狠色一区二区| 91免费观看视频| 日韩欧美一区在线| 亚洲美女精品一区| 激情综合网av| 欧美最猛性xxxxx直播| 2023国产精品自拍| 亚洲成年人影院| 成人黄色免费短视频| 日韩精品资源二区在线| 亚洲视频在线一区二区| 国产综合一区二区| 欧美日韩免费一区二区三区视频| 亚洲国产经典视频| 美女视频网站久久| 色www精品视频在线观看| 久久久99久久| 欧美bbbbb| 91毛片在线观看| 国产亲近乱来精品视频 | 狠狠v欧美v日韩v亚洲ⅴ| 色噜噜夜夜夜综合网| 国产欧美一区二区精品性色超碰| 天天色天天操综合| 91在线一区二区三区| 国产午夜亚洲精品羞羞网站| 日韩中文字幕91| 日本高清不卡一区| 国产精品网曝门| 国模大尺度一区二区三区| 欧美精品一二三| 亚洲综合无码一区二区| 成人爱爱电影网址| 337p粉嫩大胆噜噜噜噜噜91av| 午夜a成v人精品| 欧美性大战久久久| 亚洲精品第1页| 波多野结衣在线aⅴ中文字幕不卡|